Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (PEGAZUS)

Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Primary Objective:

To assess the tolerability of cabazitaxel 25 mg per body surface area (m^2) with primary prophylactic polyethylene glycol-granulocyte-colony stimulating factor (PEG-G-CSF) in terms of the incidence rate of febrile neutropenia (FN) (defined: absolute neutrophil count [ANC] <1000 per volume [mm^3] and a single temperature of >38.3 degree or a sustained temperature of ≥38 degree Celsius for more than one hour) during Cycle 1.

Secondary Objective:

To assess overall rate of FN and grade ≥3 neutropenia and diarrhea; frequencies of dose delay due to adverse events (AEs); dose reduction due to AEs; relative dose intensity; incidences of FN-related hospitalization and use of intravenous (IV) anti-infectives; tolerability according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0; prostate specific antigen (PSA) response (50% decrease); tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 if available.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: CABAZITAXEL XRP6258; Drug: PEG-G-CSF; Drug: Prednisolone; Drug: Dexchlorpheniramine or Diphenhydramine; Drug: Ranitidine; Drug: Metoclopramide, Granisetron, or Ondansetron; Drug: Dexamethasone

Detailed Description

The total duration of study is 254 days as maximum with 14 days for screening, maximum of 21 days times 10 cycles for treatment, and 30 days for follow up.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 4

Contacts and Locations

Study Locations

• Japan
  • Chuo-ku, Chiba, Japan
    • Investigational Site Number 392004
  • Kita-gun, Japan
    • Investigational Site Number 392008
  • Kobe-shi, Hyogo, Japan
    • Investigational Site Number 392007
  • Nagakute-shi, Aichi, Japan
    • Investigational Site Number 392005
  • Osaka Sayama-shi, Osaka, Japan
    • Investigational Site Number 392006
  • Shinjuku-ku, Tokyo, Japan
    • Investigational Site Number 392001
  • Yokohama-shi, Japan
    • Investigational Site Number 392009
  • Yokohama-shi, Kanagawa, Japan
    • Investigational Site Number 392002

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion criteria:

• Patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with chemotherapy including docetaxel.
• Male patients.
• Patients must have either measurable or nonmeasurable disease, or documented rising PSA levels.
• Patients signed informed consent.

Exclusion criteria:

• Age <20 at registration.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2.

• Inadequate organ and bone marrow function at registration as evidenced by:

  • Hemoglobin <10.0 g/dL.
  • ANC <5 x 10^9/L.
  • Platelet count <100 x 10^9/L.
  • Aspartate transaminase (AST) and/or alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN).
  • Total bilirubin >1.0 x ULN.
  • Serum creatinine >1.5 x ULN. Serum creatinine is 1.0-1.5 x ULN and creatinine clearance is under 60 mL/min (calculated according to Chronic Kidney Disease Epidemiology Collaboration [CKD-EP]).
• Prior isotope therapy or radiotherapy to ≥30% of bone marrow. At the first study drug administration day, patient has not elapsed 8 weeks (12 weeks for strontium-89) from the day prior isotope therapy finished.
• Prior surgery, radiation, chemotherapy, or other anticancer therapy within 4 weeks prior to enrollment in the study.
• Symptomatic peripheral neuropathy grade ≥2 (NCI CTCAE v.4.0).
• History of severe hypersensitivity reaction (grade ≥3) to polysorbate 80 containing drugs.
• Prior and other concurrent malignancy, excepted cases are as follows; basal cell carcinoma or squamous cell carcinoma of skin, or superficial (pTis, pTa, and pT1) bladder cancer (including immunotherapy) treated adequately, any other cancer completed the chemotherapy more than 5 years ago and been more than 5 years as disease free duration.
• Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus).
• Known lesion at brain or leptomeninx.
• Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment.
• Active varicella zoster infection, anti-hepatitis C virus (HCV) antibody-positive (excluding patients negative for HCV virus in blood test or non-active seropositive patients with no hepatic abnormalities [AST, ALT, etc.]), or hepatitis B surface (HBs) antigen-positive.
• Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4 or 5 (wash-out period for a one week is necessary for patients who are already on these treatments or a two-week wash-out period is necessary for patients who are already on these treatments).
• Contraindication to be used corticosteroid.
• Patients with reproductive potential who do not agree to use an accepted and effective method of contraception during the study treatment period. The definition of "effective method of contraception" will be based on the Investigator's judgment.
• Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to registration.
• Prior history of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisolone, PEG-G-CSF or G-CSF.
• Known hypersensitivity to the component of PEG-G-CSF and/or G-CSF.
• Myelogenous leukemia insufficient decrease of the number of blast in bone marrow, or found myeloblast in peripheral blood.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Cabazitaxel; 25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks. Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles.

Drug: CABAZITAXEL XRP6258; Pharmaceutical form:solution Route of administration: intravenous; Other Names: JEVTANA; Drug: PEG-G-CSF; Pharmaceutical form:solution Route of administration: subcutaneous; Other Names: G-LASTA; Drug: Prednisolone; Pharmaceutical form:tablet Route of administration: oral; Drug: Dexchlorpheniramine or Diphenhydramine; Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular; Drug: Ranitidine; Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular; Drug: Metoclopramide, Granisetron, or Ondansetron; Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular; Drug: Dexamethasone; Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients with FN (all grades) during study Cycle 1	3 weeks (during study Cycle 1)

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of patients with FN (all grades)	Up to 7 months as treatment period
Number of patients with Grade ≥3 neutropenia	Up to 7 months as treatment period
Number of patients with Grade ≥3 diarrhea	Up to 7 months as treatment period
Number of dose delays in the start of drug administration due to AEs	Up to 7 months as treatment period
Number of dose reductions due to AEs	Up to 7 months as treatment period
Percent change in relative dose intensity due to AEs	Up to 7 months as treatment period
Number of patients with FN-related hospitalization	Up to 7 months as treatment period
Number of patients who used IV anti-infective drugs	Up to 7 months as treatment period
Changes of PSA levels from baseline	Up to 7 months as treatment period
Number of patients with adverse events	Up to 7 months as treatment period

Collaborators and Investigators

• Sponsor: Sanofi

Publications and helpful links

General Publications

• Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051.

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Actual): February 1, 2016
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: May 8, 2015
• First Submitted That Met QC Criteria: May 8, 2015
• First Posted (Estimate): May 12, 2015

Study Record Updates

• Last Update Posted (Estimate): January 24, 2017
• Last Update Submitted That Met QC Criteria: January 23, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Autonomic Agents; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Dermatologic Agents; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Dopamine Agents; Serotonin Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Hypnotics and Sedatives; Anti-Anxiety Agents; Anesthetics, Local; Anti-Ulcer Agents; Anti-Allergic Agents; Sleep Aids, Pharmaceutical; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Antipruritics; Histamine H2 Antagonists; Dexamethasone; Prednisolone; Diphenhydramine; Promethazine; Granisetron; Ranitidine; Ondansetron; Metoclopramide; Dexchlorpheniramine
• Other Study ID Numbers: CABAZL07239; U1111-1155-8055 (UTN)